WASHINGTON — The investigational microbiota-based drug, RBX2660, safely and effectively prevented recurrent Clostridioides difficile infection, or rCDI, and demonstrated clinical durability 2 years after treatment, according to findings from the PUNCH open-label study presented at IDWeek.

C. difficile infections are a significant problem worldwide, primarily with respect to recurrence and the ongoing propagation of recurrence,” Ken Blount, PhD, chief scientific officer of Rebiotix Inc., said in a presentation. “As it is also becoming very clear, microbiota restoration is needed for this indication to prevent recurrence.”

Read more at Healio…